JPRN-UMIN000014999已完成未知
Comparison of Sorafenib and DEB-TACE in patients wth hepatocellular carcinoma refractory to conventional TACE. - The investigation for the therapy of hepatocellular carcinoma refractory to conventional TACE.
Musashino Red Cross Hospital0 个研究点目标入组 100 人开始时间: 2014年9月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patiets that written agreement of participation for this study was not obtained. 2)Patients whose HCC with invasion of stem of portal vein. 3)Patients with uncontrollable ascites. 4)Patients whose TMN stage of HCC is IVb. 5)Patients whose Child-Pugh is B or C. 6)Pregnant patiients. 7)Patients with iodine hypersensitivity. 8)Patients who were estimated that study entry is inappropriate by the responsible physician.
研究者
相似试验
已完成
2 期
Phase II study of sorafenib in patients with advanced hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000002972Kyorin University Hospital80
招募中
2 期
To evaluate the effect of Sorafenib with TACE for intrahepatic metastasis of hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000007488ippon medical school100
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)EUCTR2009-012576-27-PLMedical Faculty, University Magdeburg710
进行中（未招募）
1 期
Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma - SORAMICCarcinoma hepatocelular (CHC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 12.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableMedDRA version: 12.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentMedDRA version: 12.1Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableMedDRA version: 12.1Level: LLTClassification code 10049010Term: Carcinoma hepatocellularEUCTR2009-012576-27-SIMedical Faculty, University Magdeburg665
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 16.1 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrent System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10049010 Term: Carcinoma hepatocellular System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectable System Organ Class: 100000004864EUCTR2009-012576-27-NLMedical Faculty, University Magdeburg665